Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. Thank you, everyone. Good afternoon. Welcome to the 3:50 p.m. session at the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover both European and U.S. biopharma names here at the firm.
It's my great pleasure to be hosting Genmab today in a fireside chat. And with that, let me welcome CFO, Anthony Pagano; and Chief Development Officer, Judith Klimovsky.
So with that, Anthony, it's good to see you. This is your second Goldman Sachs Healthcare conference. And if you may recall, you did this with us last year where you had just announced your broad partnership for epcoritamab and some other earlier-stage assets with AbbVie. So it's great to see you again. And maybe if -- I'm just going to start conversationally just right now, and then I'll have you kind of give an introduction to the company.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |